[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335603-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335603-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","association-of-pre-existing-conditions-with-major-driver-mutations-and-pd-l1-expression-in-nsclc","Association of pre-existing conditions with major driver mutations and PD-L1 expression in NSCLC","","Objectives explore correlations between pre-existing conditions, including blood types, family history of cancer, and comorbid diseases, and genetic driver mutations plus programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer (NSCLC). Methods analyze a surgical resection cohort of 5507 patients (Jan 2014–Jul 2018) using targeted next-generation sequencing for mutations in nine cancer-related genes and immunohistochemistry for PD-L1. Logistic regression identifies significant associations.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/association-of-pre-existing-conditions-with-major-driver-mutations-and-pd-l1-expression-in-nsclc/335603/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/association-of-pre-existing-conditions-with-major-driver-mutations-and-pd-l1-expression-in-nsclc/335603.png","ImageObject",300,407,{"name":42,"@type":43},"Evangeline","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What pre-existing conditions were evaluated in this NSCLC study?","Question",{"text":63,"@type":64},"The study evaluated blood types, family history of cancer, and comorbid diseases as potential correlates of driver mutations and PD-L1 expression.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were genetic mutations and PD-L1 expression measured?",{"text":68,"@type":64},"Targeted next-generation sequencing detected mutations in nine pivotal cancer-related genes, and immunohistochemical staining assessed PD-L1 expression.",{"name":70,"@type":61,"acceptedAnswer":71},"What key associations did the study report between pre-existing conditions and driver mutations/PD-L1?",{"text":72,"@type":64},"ROS1 mutations were linked with a family history of lung cancer; EGFR L858R mutations were associated with family history of non-lung cancers and hypertension; diabetes and hepatitis B surface antigen positivity correlated with EGFR exon 19 deletions; tuberculosis history was associated with increased PD-L1 expression in immune cells.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335603,1790070171,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","Lung cancer  \nTo cite: Chen P, Zheng X, Li C, et al. Association of pre-existing conditions with major driver mutations and PD-L1 expression in NSCLC. BMJ Open Respir Res 2024;11:e002571 . doi:10.1136/ bmjresp-2024-002571  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi](https://doi). org/10.1136/bmjresp-2024- 002571) .  \nPC, XZ, CL, JL and CY contributed equally.  \nReceived 14 May 2024 Accepted 24 October 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Wenhua Liang;  \nliangwh1987@163.com and  \nDr Jianxing He;  \ndrj[ianxing.he@gmail.com](ianxing.he@gmail.com)  \nAssociation of pre-existing conditions with major driver mutations and PD-L1 expression in NSCLC  \nPeiling Chen  ,1 Xin Zheng,1 Caichen Li,1 Jianfu Li,1 Chen Yang,2 Yi Feng,1 Bo Cheng,1 Hengrui Liang  ,1 Zhichao Liu,3 Yi Zhao,1 Shan Xiong,1 Feng Li,1 Ran Zhong,1 Shuting Zhan,1 Huiting Wang,1 Yang Xiang,1 Wenhai Fu,1 Wenjun Ye,1 Bo’ao Jiang,1 Xianzhe Fan,1 Jun Liu,1 Jianxing He  ,1 Wenhua Liang  1  \nABSTRACT  \nObjectives This study aims to explore how pre-existing conditions such as blood types, family history of cancer and comorbid diseases correlate with the genetic and programmed death-ligand 1 (PD-L1) expression that contributes to the heterogeneous biological behaviours of non-small cell lung cancer (NSCLC) .  \nMaterials and methods A cohort of 5507 NSCLC patients who underwent surgical resection between January 2014 and July 2018 was studied. Targeted next-generation sequencing was used to detect mutations in nine pivotal cancer-related genes, and immunohistochemical staining was applied to assess PD-L1 expression. Logistic regression analysis was employed to identify significant correlations.  \nResults All patients underwent NGS, with 1839 were also evaluated for PD-L1 expression. Several significant findings were found: ROS1 mutations were closely associated with a family history of lung cancer (OR 7.499, 95% CI 1.094 to 30 .940, p=0 .013) . Epidermal growth factor receptor (EGFR) L858R mutations were common among patients with a family history of non-lung cancersand those with hypertension (OR 2 .089, 95% CI 1.029 to 4. 135, p=0 .037 and OR 1 .252, 95% CI 1.001 to 1.562, p=0 .048, respectively) . Pre-existing conditions such as diabetes and hepatitis B surface antigen positivity (OR 1.468, 95% CI 1.042 to 2 .047, p=0 .026 and OR 1 .373, 95% CI 1.012 to 1 .847, p=0 .038, respectively) were correlated with EGFR exon 19 deletions. RhD negativity showed potential ties to BRAF mutations (OR 0 .010, 95% CI 0.001 to 0 .252, p=0 .001) . A history of tuberculosis linked to increased PD-L1 expression in immune cells (OR 3.597, 95% CI 1.295 to 14 .957, p=0 .034) .  \nConclusion This large-scale, cross-sectional study reveals a complex interplay between genetic mutations, immunological features and pre-existing conditions in NSCLC patients, offering insights that could inform personalised treatment strategies.  \nINTRODUCTION  \nRecent advances in understanding genetic profiles and the immune landscape have revolutionised the treatment of non-small cell lung cancer (NSCLC), leading to the  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Previous studies have highlighted the role of driver mutations and PD-L1 expression in non-small cell lung cancer (NSCLC), but the association of these genetic and immunological features with pre-existing conditions, such as blood types, family history of cancer and comorbid diseases, remains unclear.\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ This study demonstrates significant correlations between pre-existing conditions and specific genetic mutations in NSCLC, such as the association of ROS1 mutations with a family history of lung cancer, epidermal growth factor receptor L858R mutations with hypertension and non","cbCaic4y92VecBk5","https://ap.wps.com/l/cbCaic4y92VecBk5","pdf",1933645,"English","# Abstract\n## Objectives\n## Materials and methods\n## Results\n## Conclusion\n# Introduction\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy","[{\"question\":\"What pre-existing conditions were evaluated in this NSCLC study?\",\"answer\":\"The study evaluated blood types, family history of cancer, and comorbid diseases as potential correlates of driver mutations and PD-L1 expression.\"},{\"question\":\"How were genetic mutations and PD-L1 expression measured?\",\"answer\":\"Targeted next-generation sequencing detected mutations in nine pivotal cancer-related genes, and immunohistochemical staining assessed PD-L1 expression.\"},{\"question\":\"What key associations did the study report between pre-existing conditions and driver mutations/PD-L1?\",\"answer\":\"ROS1 mutations were linked with a family history of lung cancer; EGFR L858R mutations were associated with family history of non-lung cancers and hypertension; diabetes and hepatitis B surface antigen positivity correlated with EGFR exon 19 deletions; tuberculosis history was associated with increased PD-L1 expression in immune cells.\"}]","Association of pre-existing conditions with major driver mutations and PD-L1 expression in NSCLC | PDF",1790011597,25]